2-((1S,2S,5S)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((1S,2S,5S)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol
• 英文别名: 2-[(1S,2S,5S)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
• 化学式: C₂₄H₄₀O₃
• 分子量: 376.6
• InChiKey: YNZFFALZMRAPHQ-VCOUNFBDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Modular transdermal delivery system and associated methods of manufacture and use
  申请人：International Bioceutical Co. LLC

  公开号：US11052055B2

  公开（公告）日：2021-07-06

  A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.

  本发明提供了一种模块化透皮给药系统，该系统包括：上部模块，其中外部背衬层与压敏粘合层层压在一起，该层在组装前由可移除的释放衬垫覆盖；以及下部模块，其中多孔储药层与皮肤接触粘合剂层压在一起，该皮肤接触粘合剂在一个实施例中是与多孔储药层基本共存的粘合层，在使用前由第二层可移除的释放衬垫保护。此外，还提供了制造和使用方法，以及通过将上部模块的压敏胶层粘贴到下部模块的多孔储药层上而制造的组装式透皮给药系统。
• MODULAR TRANSDERMAL DELIVERY SYSTEM AND ASSOCIATED METHODS OF MANUFACTURE AND USE
  申请人：International Bioceutical Co. LLC

  公开号：US20180296498A1

  公开（公告）日：2018-10-18

  A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.
• Modular Transdermal Delivery Systems for the Treatment of Insomnia and Anxiety
  申请人：International Bioceutical Co. LLC

  公开号：US20180311181A1

  公开（公告）日：2018-11-01

  Modular transdermal delivery system components are provided that are assembled to provide a modular transdermal drug delivery system for the administration of a pharmacologically active agent for treating insomnia, anxiety, or both insomnia and anxiety. The components include: an upper module with an outer backing layer, a pressure-sensitive adhesive (PSA) layer laminated thereto, and a removable release liner; and at least two lower modules with a porous drug reservoir layer capable of adhering to the PSA layer of the upper module and loaded with a pharmaceutical formulation containing an effective amount of the pharmacologically active agent, with a skin-contact adhesive affixed to the drug reservoir layer. The lower modules differ from each other in at least one respect, e.g., with respect to thickness, drug reservoir volume, active agent, or dosage, such that prior to use the upper module any lower module can be selected and assembled with the upper module to provide a laminated transdermal delivery system. Related systems and methods of manufacture and use are also provided.
• Modular Transdermal Delivery Systems for the Treatment of Pain and Inflammation
  申请人：International Bioceutical Co. LLC

  公开号：US20180311180A1

  公开（公告）日：2018-11-01

  Modular transdermal delivery system components are provided that are assembled to provide a modular transdermal drug delivery system for the administration of a pharmacologically active agent for treating pain, inflammation, or both pain and inflammation. The components include: an upper module with an outer backing layer, a pressure-sensitive adhesive (PSA) layer laminated thereto, and a removable release liner; and at least two lower modules with a porous drug reservoir layer capable of adhering to the PSA layer of the upper module and loaded with a pharmaceutical formulation containing an effective amount of the pharmacologically active agent, with a skin-contact adhesive affixed to the drug reservoir layer. The lower modules differ from each other in at least one respect, e.g., with respect to thickness, drug reservoir volume, active agent, or dosage, such that prior to use the upper module any lower module can be selected and assembled with the upper module to provide a laminated transdermal delivery system. Related systems and methods of manufacture and use are also provided.
• CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS
  申请人：GADEK Thomas Richard

  公开号：US20210038559A1

  公开（公告）日：2021-02-11

  This invention provides processes and compositions for enhancing the immunogenicity of tumor or infected cells by increasing expression of major histocompatibility complex (MHC) class I surface molecules. Tumor cells often circumvent immune recognition by reducing or eliminating MHC expression. The lack of MHC on their surface allows tumor cells to evade immune detection and enables uncontrolled growth. Similarly, certain viral or microbial infections result in MHC class I downregulation and the resulting immune evasion. With a unique reporter assay, we have determined that some cannabinoid compounds and structural analogs can increase MHC class I expression on tumor cells grown in cell culture. The increase of tumor and infected cell MHC class I expression will enable detection and destruction by cytotoxic T-lymphocyte cells. The process and compositions increase the immunogenicity of the target cells, e.g. tumor or infected cells, to enhance their destruction by cytotoxic lymphocytes. When administered in combination, such compositions may enhance the activity of immune-oncology and anti-infectious disease agents.